cancerinduc
muscl
wast
one
hallmark
cachexia
multifactori
syndrom
repres
one
import
comorbid
oncolog
patient
occurr
cachexia
markedli
complic
manag
cancer
patient
neg
imping
toler
respons
antineoplast
treatment
worsen
qualiti
life
reduc
surviv
particular
death
cancer
due
cachexia
rather
tumor
year
ago
classif
cachexia
propos
defin
three
differ
stage
precachexia
cachexia
refractori
cachexia
prognosi
progress
worsen
go
patient
precachexia
refractori
cachexia
regard
earlier
anticachexia
treatment
set
better
reason
research
cachexia
focus
two
main
goal
find
biomark
use
earli
identif
condit
still
latent
cachexia
ii
defin
treatment
protocol
use
delay
progress
precachexia
refractori
cachexia
skelet
muscl
wast
cancer
patient
good
prognost
valu
predictor
reduc
toler
chemotherapi
andor
surgeri
decreas
abil
perform
daili
activ
shorten
surviv
addit
recent
data
report
loss
muscl
mass
neg
affect
qualiti
life
cancer
patient
correl
might
occur
irrespect
surviv
rate
poor
qualiti
life
one
promin
invalid
consequ
cancer
cachexia
investig
mechan
underli
cancerinduc
muscl
wast
even
relev
design
therapeut
strategi
also
take
account
patient
wellb
possibl
underestim
occurr
muscl
mass
deplet
exist
sinc
first
approach
clinic
evalu
patient
obtain
inform
bodi
weight
bodi
mass
index
bmi
howev
face
bodi
weight
loss
andor
normal
bmi
reduc
muscl
mass
might
well
occur
mask
fat
water
content
anoth
relev
point
frequent
poorli
taken
consider
loss
muscl
mass
like
exacerb
anticanc
treatment
present
differ
mechan
propos
lead
muscl
wast
cancer
host
among
alter
protein
energi
metabol
impair
myogenesi
sever
factor
may
contribut
alter
reduc
calori
intak
hormon
unbal
system
inflamm
cancerdriven
product
proinflammatori
cytokin
play
relev
role
tumor
progress
markedli
contribut
cachexia
inde
cancer
patient
system
inflamm
correl
increas
rest
energi
expenditur
reduc
surviv
rate
along
line
increas
circul
level
tumor
necrosi
factor
inf
recent
growth
differenti
factor
report
cachect
cancer
patient
link
exist
cytokin
cachexia
led
inclus
antiinflammatori
drug
treatment
protocol
present
review
focu
strategi
abl
modul
metabol
may
reveal
use
preventdelay
cancerinduc
muscl
wast
sever
piec
evid
suggest
intracellular
proteolyt
system
skelet
muscl
cancer
host
pois
toward
activ
physiolog
level
figur
particularli
relev
regard
pathway
depend
ubiquitinproteasom
autophagi
former
mainli
degrad
shortliv
regulatori
protein
latter
get
rid
structur
protein
organel
experiment
human
cancer
cachexia
associ
increas
activ
ubiquitinproteasom
pathway
interest
alter
molecular
biochem
marker
proteasom
activ
observ
gastric
cancer
patient
evid
bodi
weight
loss
support
need
detect
cachexia
earli
possibl
modul
ubiquitinproteasom
proteolyt
system
howev
gener
find
cancer
cachexia
shown
studi
report
differ
activ
respect
control
muscl
patient
affect
nonsmallcel
lung
cancer
nsclc
esophag
cancer
involv
autophagiclysosom
proteolysi
muscl
wast
recogn
last
fifteen
year
two
main
reason
account
delay
autophagi
consid
typic
oper
skelet
muscl
respons
stress
condit
belief
definit
abandon
autophagi
clearli
demonstr
fast
mice
overexpress
green
fluoresc
proteinlabel
ii
studi
detect
autophagi
easi
sinc
atg
gene
discov
number
studi
report
autophag
system
overactiv
without
reach
complet
cargo
degrad
muscl
tumorbear
anim
cancer
patient
particular
despit
autophag
flux
enhanc
mice
bear
tumor
autophagosom
accumul
like
due
exhaust
lysosom
compart
similar
pattern
could
also
observ
cancer
patient
suggest
accumul
proteasom
lysosom
howev
directli
degrad
intact
myofila
regard
preliminari
cleavag
propos
oper
proteolyt
system
depend
caspas
calpain
latter
cystein
proteas
normal
inact
local
cytosol
compart
intracellular
concentr
increas
inact
calpain
transloc
cell
membran
becom
activ
autoproteolysi
system
also
includ
calpastatin
physiolog
inhibitor
substrat
activ
calpain
increas
calpain
express
report
muscl
tumorbear
anim
rat
transplant
yoshida
hepatoma
show
progress
reduct
calpastatin
level
increas
vitro
cleavag
specif
fluorogen
substrat
recent
calpain
activ
also
demonstr
mice
bear
colon
carcinoma
increas
unchang
muscl
calpain
express
report
cancer
patient
sever
line
evid
show
proinflammatori
cytokin
act
trigger
least
contributor
cancerinduc
protein
hypercatabol
briefli
data
obtain
experiment
model
human
patholog
demonstr
cytokin
lead
reduc
rate
protein
synthesi
parallel
enhanc
protein
breakdown
account
loss
muscl
mass
effect
depend
least
part
activ
transcript
factor
shown
experiment
human
cancer
cachexia
patient
cancerinduc
muscl
wast
also
associ
anoth
proinflammatori
cytokin
name
tnflike
weak
induc
apoptosi
tweak
therapeut
approach
mainli
pursu
research
counteract
enhanc
muscl
protein
breakdown
long
specif
target
differ
proteolyt
system
result
howev
realli
clarifi
issu
sinc
discoveri
musclespecif
ubiquitin
ligas
consid
good
target
interfer
protein
breakdown
involv
determin
substratespecif
proteasom
degrad
rate
among
enzym
belong
famili
first
describ
respect
involv
degrad
structur
protein
protein
contribut
cell
prolifer
differenti
surviv
subsequ
member
came
recent
shown
contribut
denerv
fastingmedi
muscl
loss
well
cancerinduc
muscl
wast
unpublish
data
genet
approach
specif
target
ubiquitin
ligas
prove
effect
protect
muscl
protein
deplet
howev
present
use
enzym
therapeut
target
muscl
wast
valid
yet
side
inhibit
proteasom
activ
mean
pharmacolog
inhibitor
effect
model
muscl
atrophi
total
unabl
protect
tumorbear
anim
muscl
wast
contrast
find
year
ago
studi
report
inhibit
ubiquitinproteasom
pathway
abl
improv
experiment
cancer
cachexia
howev
rather
unspecif
inhibitor
abl
block
also
calpain
autophagi
final
carfilzomib
irrevers
select
inhibitor
proteasom
chymotrypsinlik
activ
shown
improv
cachexia
tumorbear
mice
inhibit
muscl
protein
breakdown
improv
howev
associ
reduc
tumor
burden
could
real
mechan
underli
benefici
effect
treatment
sever
line
evid
propos
modul
autophagi
could
use
improv
cancerassoci
muscl
wast
regard
musclespecif
gene
strategi
aim
silenc
one
protein
involv
autophagosom
format
show
suppress
autophagi
host
unabl
rescu
myofib
diamet
unpublish
data
addit
pharmacolog
inhibit
autophagi
mice
host
tumor
lead
death
anim
suggest
lysosom
degrad
mandatori
sustain
requir
energi
substrat
tumor
host
least
face
termin
phase
cancer
growth
way
round
excess
stimul
muscl
autophagi
experiment
obtain
overexpress
exacerb
muscl
atrophi
tumorbear
mice
unpublish
data
activ
autophagi
mean
mtor
inhibitor
rapamycin
shown
posit
affect
skelet
muscl
host
discrep
might
depend
fact
mtor
inhibit
affect
stressinduc
autophagi
hyperexpress
target
basal
autophagi
despit
literatur
report
data
support
involv
proteolysi
pathogenesi
cancerinduc
muscl
wast
protein
hypercatabol
downregul
prepar
isol
muscl
obtain
tumorbear
anim
incub
presenc
calpain
inhibitor
recent
pharmacolog
genet
approach
aim
inhibit
proteolyt
system
abl
prevent
delay
cancerinduc
muscl
wast
although
contrast
result
report
regard
interf
specif
proteolyt
system
seem
appropri
approach
preventdelay
cancerinduc
muscl
wast
modul
bulk
protein
turnov
appear
promis
regard
antiinflammatori
approach
reveal
abl
improv
muscl
protein
turnov
tumorbear
mice
recent
administr
formoterol
agonist
tumorbear
anim
reveal
abl
revers
muscl
wast
effect
mainli
exert
stimul
protein
synthesi
inhibit
protein
degrad
rate
particular
ubiquitinproteasom
autophagiclysosom
proteolyt
system
downregul
formoterolreceiv
anim
unpublish
data
present
one
studi
evalu
effect
formoterol
combin
megestrol
acet
cachect
cancer
patient
result
suggest
muscl
size
strength
improv
treatment
although
trial
need
draw
clearcut
evid
report
depend
situat
reduc
normal
even
increas
muscl
protein
synthesi
rate
shown
cancer
cachexia
due
rapid
develop
cachexia
tumorbear
anim
frequent
show
reduc
protein
synthesi
rate
although
gener
find
inde
rat
bear
hepatoma
usual
die
day
tumor
transplant
show
muscl
protein
synthesi
rate
compar
healthi
anim
situat
complex
studi
human
patholog
reduc
muscl
protein
synthesi
report
mani
year
ago
patient
affect
differ
type
tumor
recent
prostat
cancer
patient
contrari
van
dijk
et
al
report
baselin
protein
synthesi
rate
higher
control
valu
cachect
patient
affect
pancreat
cancer
also
intermedi
result
avail
literatur
myofibrillar
protein
synthesi
rate
analyz
healthi
peopl
weightstabl
weightlos
gastrointestin
cancer
patient
found
compar
among
differ
group
similarli
chang
whole
bodi
protein
synthesi
report
nsclc
patient
possibl
modul
protein
synthesi
order
correct
muscl
atrophi
simpli
provid
environ
permiss
mainten
muscl
mass
long
studi
mani
approach
test
consist
nutrit
strategi
molecular
modul
aim
push
muscl
metabol
toward
anabol
approach
reveal
unsuccess
give
rise
idea
anabol
resist
occur
cancer
cachexia
provid
exampl
convent
nutrit
supplement
infus
amino
acid
cocktail
stimul
muscl
protein
synthesi
advanc
cancer
patient
along
line
studi
aim
stimul
anabol
pathway
depend
pharmacolog
genet
mean
succeed
improv
muscl
wast
tumorbear
anim
recent
howev
patient
yet
consid
refractori
cachect
propos
display
anabol
window
could
exploit
nutrit
intervent
anabolisminduc
strategi
exampl
patient
stage
iii
iv
nsclc
show
normal
anabol
respons
hyperaminoacidemia
isoaminoacidemia
suggest
high
substrat
avail
relev
induc
anabol
cancer
host
consist
muscl
protein
synthesi
could
stimul
advanc
cancer
patient
high
protein
formula
versu
convent
nutrit
supplement
observ
point
possibl
overcom
anabol
resist
occur
cancer
patient
provid
specif
enrich
nutrit
supplement
stimul
anabol
exert
sever
mean
particularli
interest
regard
ghrelin
mediat
releas
stomach
fast
calor
restrict
modul
ghrelin
level
exert
remark
effect
energi
protein
metabol
inhibit
autophagi
condit
character
system
inflamm
administr
ghrelin
tumorbear
anim
improv
food
intak
bodi
weight
lean
bodi
mass
chemotherapyinduc
toxic
ghrelin
ghrelin
analogu
current
test
clinic
trial
among
anamorelin
recent
shown
improv
lean
bodi
mass
total
bodi
mass
hand
grip
strength
patient
affect
nsclc
studi
howev
show
anamorelin
administr
cancer
patient
increas
bodi
weight
improv
faact
score
enhanc
hand
grip
strength
addit
necessari
synthes
protein
free
amino
acid
faa
also
act
regul
protein
metabol
particular
plasma
faa
even
repres
small
fraction
total
amino
acid
pool
main
sourc
metabol
activ
nitrogen
compound
among
faa
essenti
amino
acid
report
stimul
protein
synthesi
inhibit
protein
degrad
role
mainli
play
three
branch
chain
amino
acid
bcaa
leucin
particular
alter
amino
acid
metabol
frequent
featur
cancerinduc
muscl
wast
reduc
amino
acid
uptak
gener
observ
cancer
patient
mainli
due
occurr
anorexia
also
lead
decreas
insulin
secret
decreas
amino
acid
avail
insulin
level
inhibit
anabol
pathway
depend
mtor
result
downregul
protein
synthesi
rate
stimul
protein
degrad
inhibit
mtor
signal
cancer
cachexia
enforc
proinflammatori
cytokin
reduc
amino
acid
uptak
muscl
also
report
deriv
alter
amino
acid
transport
inde
soleu
muscl
tumorbear
rat
activ
system
decreas
chang
observ
system
l
asc
interest
shown
impair
amino
acid
transport
tumorbear
rat
plasma
glutamin
level
shown
significantli
reduc
tumorbear
rat
respect
healthi
anim
interest
reduc
glutamin
avail
could
activ
metabol
sensor
adenosin
monophosphateactiv
protein
kinas
ampk
see
final
leucin
oxid
markedli
increas
muscl
rat
bear
yoshida
hepatoma
consist
enhanc
activ
bcaa
dehydrogenas
report
rat
bear
walker
carcinoma
sever
studi
propos
amino
acid
supplement
mean
improv
cancerinduc
muscl
wast
experiment
model
cancer
cachexia
bcaa
shown
attenu
loss
muscl
mass
underli
mechan
effect
clear
although
downregul
protein
degrad
stimul
protein
synthesi
hypothes
recent
metabolom
alter
propos
basi
posit
effect
exert
leucinerich
diet
cachexia
rat
bear
walker
carcinoma
absenc
effect
tumor
mass
clinic
studi
bcaa
propos
improv
anorexia
thu
remov
partial
least
one
mechan
account
reduc
amino
acid
uptak
studi
support
benefici
role
bcaa
muscl
protein
metabol
although
confirm
larger
random
blind
placebocontrol
trial
betahydroxybetamethylbutyr
hmb
metabolit
leucin
shown
improv
muscl
wast
experiment
cancer
cachexia
mainli
inhibit
protein
degrad
rather
stimul
protein
synthesi
recent
hmb
propos
effect
leucin
prevent
bodi
weight
loss
tumorbear
anim
effect
howev
could
depend
model
system
chosen
sinc
hmb
appear
abl
modul
muscl
mass
mice
bear
tumor
costelli
et
al
unpublish
observ
situat
even
confus
human
cachexia
increas
hemoglobin
level
fatfre
mass
report
advanc
cancer
patient
administ
nutrit
supplement
contain
hmb
arginin
glutamin
anoth
studi
howev
abl
demonstr
benefici
effect
supplement
cancer
patient
suggest
effect
hmb
clinic
practic
still
unclear
deserv
investig
glutamin
supplement
report
attenu
muscl
protein
wast
cancer
patient
well
improv
energi
balanc
rat
bear
walker
tumor
final
promis
data
avail
possibl
treat
cancer
host
lcarnitin
amino
acid
deriv
play
role
fatti
acid
metabol
energi
product
neg
energi
balanc
gener
result
reduc
product
increas
expenditur
frequent
occurr
cancer
patient
rest
energi
expenditur
ree
frequent
increas
like
due
enhanc
thermogenesi
occurr
reduc
physic
activ
particularli
advanc
cancer
patient
paradox
lead
net
decreas
total
energi
expenditur
increas
thermogenesi
consist
observ
cachect
tumorbear
anim
express
brown
adipos
tissu
bat
specif
uncoupl
protein
higher
control
ubiquit
express
bat
muscl
level
increas
skelet
muscl
similarli
muscl
mrna
level
higher
weightlos
nonweightlos
cancer
patient
control
increas
ree
cancer
cachexia
new
observ
howev
recent
underli
mechan
start
clarifi
central
point
regard
play
muscl
mitochondria
compart
markedli
affect
tumor
host
inde
morpholog
function
alter
report
experiment
tumorbear
anim
particular
mitochondri
uncoupl
reduc
oxid
capac
associ
myofib
shift
oxid
glycolyt
fiber
impair
mitochondri
compart
result
decreas
atp
product
lead
energi
deficit
becom
even
wors
sinc
coupl
steadili
increas
ree
consist
reduc
atp
level
increas
activ
energi
sensor
ampk
shown
muscl
tumorbear
anim
lack
appropri
energi
suppli
result
compromis
cell
function
reduc
contractil
forc
gener
lead
loss
muscl
mass
strength
sever
factor
lead
mitochondri
alter
skelet
muscl
among
proinflammatori
cytokin
play
major
role
inde
activ
induc
report
reduc
muscl
oxid
capac
express
factor
regul
mitochondri
biogenesi
similar
observ
report
inflammationdriven
pathway
activ
physiolog
level
addit
proinflammatori
mediat
also
oxid
stress
due
reactiv
oxygen
nitrogen
speci
level
exceed
compens
capac
intracellular
antioxid
system
contribut
mitochondri
function
impair
regard
sever
studi
sustain
involv
oxid
stress
cancerinduc
muscl
wast
although
clearcut
caus
evid
still
lack
et
al
unpublish
data
figur
mitochondria
crucial
mainten
muscl
oxid
metabol
emerg
rout
activ
order
avoid
mitochondri
dysfunct
particular
mitochondri
biogenesi
dynam
well
dispos
damag
organel
mainli
mitophagi
promot
figur
way
round
impair
function
emerg
rout
could
trigger
accumul
alter
mitochondria
result
reduc
muscl
oxid
metabol
regard
express
peroxisom
proliferatoractiv
master
regul
mitochondri
biogenesi
oxid
metabol
shown
reduc
skelet
muscl
tumorbear
mice
although
constant
find
mitochondria
dynam
repres
balanc
fission
fusion
process
shown
alter
experiment
cancer
cachexia
cancer
patient
regard
impair
mitochondri
dynam
could
drive
hyperactiv
muscl
protein
breakdown
like
pathway
depend
ampk
foxo
eventu
lead
muscl
wast
autophagi
mitophagi
main
mechan
respons
dispos
alter
mitochondria
also
mitophagi
report
impair
cancer
cachexia
shown
observ
mrna
increas
muscl
cancer
patient
similarli
protein
level
increas
muscl
mice
bear
lewi
lung
carcinoma
whole
observ
suggest
addit
mitochondria
biogenesi
dynam
also
dispos
perturb
skelet
muscl
tumor
host
thu
contribut
mitochondri
dysfunct
reduc
muscl
oxid
metabol
sever
strategi
propos
improv
energi
metabol
act
mitochondria
first
perhap
simplest
one
theori
least
exercis
train
particular
combin
resist
endur
exercis
two
type
train
affect
differ
complementari
target
abl
improv
forc
product
metabol
adapt
respect
particular
relev
observ
endur
train
report
increas
number
mitochondria
drive
myofibertyp
shift
glycolyt
oxid
thu
specif
target
alter
characterist
occur
skelet
muscl
tumor
host
howev
potenti
favor
effect
exploit
systemat
practic
exercis
even
moder
level
may
easi
task
cancer
patient
frequent
present
chronic
fatigu
comorbid
eventu
lead
exercis
intoler
point
support
observ
mice
benefit
exercis
train
suggest
effort
exercis
alreadi
compromis
anim
damag
rather
protect
consist
excess
endur
exercis
associ
increas
mitochondri
fission
absenc
mitophagi
induct
last
year
possibl
mimic
effect
exercis
drug
gain
grow
consensu
posit
side
strategi
allow
overcom
poor
patient
complianc
exercis
train
possibl
occurr
exercis
intoler
neg
part
gener
exercis
mimick
drug
total
recapitul
effect
exercis
sens
drug
properli
hit
target
howev
could
good
compromis
exercis
train
propos
patient
present
sever
option
investig
exercisemimick
strategi
pharmacolog
also
genet
approach
propos
latter
consist
manipul
abl
increas
level
skelet
muscl
regard
improv
exercis
capac
oxid
metabol
report
mice
specif
overexpress
factor
muscl
resembl
phenotyp
induc
endur
train
overexpress
shown
interfer
muscl
atrophi
induc
activ
pathway
improv
cancerinduc
muscl
wast
tumorbear
mice
although
contrast
data
previous
report
sever
class
drug
propos
modul
energi
metabol
among
activ
ampk
sirtuin
trimetazidin
tmz
differ
compound
resveratrol
metformin
quercetin
aicar
activ
ampk
regard
aicar
administr
shown
imping
exercis
capac
oxygen
consumpt
fatti
acid
oxid
muscl
atrophi
induc
angiotensin
ii
prevent
treatment
aicar
drug
also
reveal
abl
activ
autophagi
improv
muscl
phenotyp
dystroph
mdx
mice
anim
bear
tumor
metformin
administr
shown
improv
sarcopenia
age
muscl
wast
sever
burn
patient
propos
use
treat
muscl
wast
cancer
cachexia
ampk
activ
also
induc
resveratrol
demonstr
observ
mice
refractori
resveratrolinduc
increas
mitochondri
biogenesi
endur
exercis
capac
consist
obes
men
receiv
resveratrol
show
improv
inflamm
ampk
activ
increas
express
protein
level
final
ampkstabil
peptid
report
improv
white
adipos
tissu
wast
tumor
host
belong
class
deacetylas
deregul
age
differ
chronic
diseas
includ
cancer
also
involv
regul
energi
homeostasi
express
induc
respons
calor
restrict
activ
skelet
muscl
ampk
specif
overexpress
muscl
result
fasttoslow
myofib
type
transit
produc
oxid
phenotyp
consist
musclespecif
transgen
mice
expos
fast
denerv
show
reduc
express
atrogen
comparison
wildtyp
litterm
final
improv
muscl
phenotyp
report
doubl
transgen
mice
addit
ampk
resveratrol
also
activ
regard
part
abovedescrib
effect
exert
resveratrol
deriv
modul
acetyl
state
synthet
select
activ
also
avail
plasma
lipid
profil
insulin
sensit
improv
healthi
volunt
administr
studi
actual
avail
action
muscl
mass
function
regard
appear
reduc
deplet
muscl
mass
due
fast
inact
least
part
increas
express
tmz
metabol
modul
block
fatti
acid
oxid
shift
atp
product
glucos
oxid
improv
cell
energi
metabol
inde
atp
synthesi
fatti
acid
requir
oxygen
glucos
oxid
along
line
shift
glucos
oxid
improv
use
avail
oxygen
possibl
increas
metabol
effici
skelet
muscl
function
tmz
shown
increas
size
cultur
myotub
improv
heart
metabol
exercis
capac
patient
suffer
chronic
stabl
angina
administ
age
anim
tmz
result
increas
muscl
strength
final
treatment
mice
tmz
resembl
benefit
trigger
exercis
among
fasttoslow
myofib
phenotyp
shift
upregul
oxid
metabol
enhanc
grip
strength
increas
molinari
et
al
unpublish
relev
fatti
acid
oxid
cachexia
also
support
recent
studi
show
sever
tumor
cell
line
abl
releas
proinflammatori
mediat
result
enhanc
fatti
acid
oxid
activ
signal
skelet
muscl
well
tissu
wast
occur
addit
studi
also
show
treatment
tumorbear
anim
etomoxir
inhibitor
fatti
acid
oxid
rescu
muscl
mass
bodi
weight
complex
network
metabol
alter
sustain
hypercatabol
energi
deficit
system
inflamm
milieu
underli
cancer
cachexia
becom
overtli
detect
advanc
cancer
patient
perturb
like
take
place
earli
cours
diseas
least
molecular
level
protein
energi
dysmetabol
cachexia
quit
well
recogn
howev
avail
therapeut
strategi
although
frequent
promis
preclin
point
view
yet
reach
valid
use
clinic
practic
sever
drug
identifi
experiment
studi
current
test
clinic
trial
abil
improv
muscl
metabol
cancer
patient
emerg
strategi
aim
interf
intestin
microbiota
previous
report
improv
cachexia
preclin
model
avail
result
experiment
clinic
studi
howev
clearli
indic
singletarget
therapi
hardli
success
treatment
cachexia
regard
view
multidirect
approach
select
tailor
whenev
possibl
person
gain
grow
consensu
approach
reli
nutrit
counsel
pharmacolog
treatment
antiinflammatori
anticatabol
drug
also
includ
exercis
train
andor
exercisemimick
agent
regard
exercis
mimet
could
mere
replac
exercis
train
deplet
patient
also
improv
exercis
toler
effect
precachect
individu
thu
amplifi
benefici
action
exercis
last
least
treatment
aim
preventingcorrect
metabol
alter
underli
cancerinduc
muscl
wast
might
also
imping
tumortarget
therapi
improv
effect
andor
enhanc
patient
toler
chemotherapi
addit
metabol
modul
could
also
directli
affect
tumor
growth
case
exampl
exercis
shown
prevent
least
delay
tumor
growth
